Topoisomerase i expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer

Masahide Ikeguchi, Yosuke Arai, Yoshihiko Maeta, Keigo Ashida, Kuniyuki Katano, Toshiro Wakatsuki

Research output: Contribution to journalReview articlepeer-review

33 Citations (Scopus)

Abstract

Irinotecan (CPT-11) is used as a first- and second-line chemotherapy for advanced or recurrent colorectal cancer (CRC). However, only 20%-30% of patients show an objective response to CPT-11 and the drug has severe toxicities, such as delayed-onset diarrhea, neutropenia, nausea, and vomiting. It is important to select patients who will demonstrate sensitivity to CPT-11 treatment to avoid unnecessary drug toxicities and to introduce anticancer treatment benefits to CRC patients. DNA topoisomerase I (Topo I) is essential for vital cellular processes such as DNA replication, transcription, translation, recombination, and repair. This article reviews the possibility of assessing Topo I protein expression in tumors as a biological marker for CPT-11 treatment in CRC.

Original languageEnglish
Pages (from-to)1196-1199
Number of pages4
JournalSurgery Today
Volume41
Issue number9
DOIs
Publication statusPublished - 09-2011
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Surgery

Fingerprint Dive into the research topics of 'Topoisomerase i expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer'. Together they form a unique fingerprint.

Cite this